You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

Displaying 202211 - 202220 of 207728 results
  1. SELF-NEUTRALIZING OLIGONUCLEOTIDES WITH ENHANCED CELLULAR UPTAKE

    SBC: ZATA PHARMACEUTICALS, INC.            Topic: NIGMS

    DESCRIPTION (provided by applicant): There is enormous potential of oligonucleotides (ON) as therapeutics, but the challenge remains how to effectively deliver ON into cells. Currently, there are no effective and reliable ways of delivery. Outer cell membranes resist the cellular uptake of charged ON, and charges-eliminating backbone modifications such as those in peptide nucleic acids (PNA) and m ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  2. An efficient directed cell migration assay

    SBC: Platypus Technologies, LLC            Topic: NIGMS

    Project Summary The goal of this SBIR project is to design and develop an efficient, automation- compatible Directed Cell Migration (DCM) 96-well Assay that distinguishes chemokinetic from chemotactic behavior. Cell migration is currently assayed using trans-membrane well inserts, microfluidic systems and various versions of scratch assays. These methods are expensive and provide inconsistent dat ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  3. Software for Fragment-based Design of Covalent Inhibitors

    SBC: ACPHARIS            Topic: NIGMS

    DESCRIPTION (provided by applicant): Covalent drugs represent a significant portion of current pharmaceuticals, with the top 26 having sales of over 30B in the US alone. While in the past target-directed drug discovery projects rarely pursued covalent binders due to safety concerns, the industry is increasingly considering the use of targeted covalent inhibitors (TCIs) that utilize soft reactive ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  4. Semiconducting Polymer Dots for Multiplexed Assays

    SBC: LAMPROGEN INC            Topic: NIGMS

    DESCRIPTION (provided by applicant): Fluorescence based techniques play an essential role in modern cell biology and biomedical research. Further development of these techniques has been hindered by the lack of suitable fluorescent probes. To overcome thischallenge, various fluorescent nanoparticles have been developed. Among those, conjugated polymer dots (Pdots) exhibited superior properties suc ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  5. Selective inhibitors of deubiquitylases

    SBC: LIFESENSORS, INC.            Topic: NIGMS

    DESCRIPTION (provided by applicant): In the last decade there has been an explosive growth in the field of ubiquitin research, with approximately 530 human genes predicted to encode enzymes involved in the conjugation and deconjugation of ubiquitin. Of these 95 encode deubiquitylases (DUBs) and these enzymes have become the target of many on-going drug discovery efforts. All DUBs carry-out the enz ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  6. GMP Synthesis and Binding Studies of a Molecular Probe to Glycosaminoglycans

    SBC: IONIC PHARMACEUTICALS, LLC            Topic: NIGMS

    Abstract Currently, there are no molecular probes that are specifically designed for quantitative imaging of articular cartilage health. In osteoarthritis (OA), the articular cartilage becomes degraded with loss of glycosaminoglycans (GAGs) from the cartilage matrix serving as an early biomarker of the disease process. As such, there are clinical opportunities to mitigate cartilage damage in patie ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  7. Improved Probe Tips for Biomedical Atomic Force Microscopy via Batch Wafer-Scale

    SBC: TIPTEK, LLC            Topic: NIGMS

    Project Summary/Abstract This SBIR grant funds efforts to perfect and scale up a newly patented process for fabricating ultrasharp and hard probe tips for making images of biological specimens. Scanning probe microscopy (SPM) methods such as atomic force microscopy (AFM) create images of surfaces by rastering a probe across the surface. The probe itself consists of a tip (which interacts with the ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  8. High Integrity and High Yield DNA Extraction Using a Nanostructured Surface

    SBC: Circulomics Inc.            Topic: NIGMS

    High Integrity and High Yield DNA Extraction Using a Nanostructured Surface DNA/RNA extraction is a critical first step that underpins nearly all of molecular biology. Phenol/chloroform precipitation remains the gold standard when the highest DNA integrity, yield, and purity are needed. However, the significant manual skill and dexterity required makes this method labor intensive, low throughput, ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  9. Novel Hybrid Growth Factor for Immune Reconstitution in Sepsis

    SBC: Panorama Research Incorporated            Topic: NIGMS

    Abstract Novel Hybrid Growth Factor for Immune Reconstitution in Sepsis Sepsis is a major clinical problem with more than a 40% mortality rate, and is the leading cause of death in intensive care units. Despite a great deal of investment of time and moneyin basic and clinical research including more than 40 clinical trials, there is no FDA-approved drug for sepsis. Historically, experimental seps ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  10. Riboswitch Based Methyltransferase HTS Assay for Epigenetic Drug Discovery

    SBC: Bellbrook Labs, LLC            Topic: NIGMS

    DESCRIPTION (provided by applicant): Epigenetic regulation of gene expression via methylation has been implicated in diverse diseases including cancer, diabetes and inflammation, and high throughput screening for histone methyltransferase (HMT) inhibitorsis an area of intense drug discovery effort. However, there are significant shortcomings with existing HMT enzyme assay methods, and these are sl ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government